AUTHORS
Meletios-Athanasios (Thanos) C. Dimopoulos, MD, Ioannis Ntanasis-Stathopoulos, MD2, Maria Gavriatopoulou, MD3, Foteini Theodorakakou, MD4, Panagiotis Malandrakis, MD, MSc, PhD5, Eirini Solia, MD6, Aikaterini Vlachou7, Evangelos Eleutherakis Papaiakovou, MD8, Nikolaos Kanellias, MD, PhD9, Ilias Katsadouros, MD10, Panagiotis Boutsikos, MD11, Aikaterini Nikolopoulou, MD12, Magdalini Migkou13, Stavroula Giannouli14, Panagiotis Tsirigotis, MD, PhD15, Asimina Papanikolaou16, Evangelos Terpos, MD17, Efstathios Kastritis, MD18
AFFILIATIONS
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
7 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
8 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
9 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
10 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
11 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
12 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
13 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
14 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
15 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
16 Evangelismos Hospital, Athens, Greece
17 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
18 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
ABSTRACT
Backgorund: Functional high-risk (FHR) myeloma (MM) is commonly defined as disease relapsing within 18 months of treatment initiation, across multiple studies, and is associated with poor outcomes irrespective of baseline risk stratification. AntiCD38-based triplet or quadruplet (quad) induction therapy resulted in significant improvements in the depth of response as well as progression-free survival. From a clinical standpoint, recognizing FHR patients (pts) would prioritize novel (such as T-cell engaging therapies and their combinations) over conventional approaches. However, the outcomes of pts treated with modern regimens that fail to respond to or relapse early to primary therapy are not well characterized, while the previous definition of FHR needs to be re-evaluated.
Methods: We analyzed the outcomes of consecutive pts treated with antiCD38 induction regimens in the Department of Clinical Therapeutics, Athens, either quads (antiCD38, PI, lenalidomide, dexamethasone) or antiCD38 triplets (i.e antiCD38 with either lenalidomide or PI+/-chemo and dexamethasone), with or without ASCT as consolidation; pts also received continuous therapy/maintenance with antiCD38+/-lenalidomide. We evaluated initially the impact of refractory disease/relapse (PD) within 18 months (FHR18) with minimum follow up of 18 months (n=336 pts), of FHR24 (n=277, minimum follow up of 24 months) and FHR36 (n=164, minimum follow up of 36 months).
Results: Among evaluable pts, 11% were FHR18 and 10% died without MM progression; thus, excluding non-PD related deaths, FHR18 rate was 12.2%. Among those ASCT-treated, FHR18 was 4.4% and among pts that did not receive ASCT the FHR18 rate was 15%. FHR18 occurred in 10% of pts on quads vs 14.5% of pts on antiCD38 triplets, however, among ASCT-treated, FHR occurred in 3% of pts on quads vs 5.4% on triplets and among the non-ASCT-treated in 17.5% and 17.6% respectively. The 2-year OS post PD was 57% for FHR18 vs 92% for the rest of the pts, corresponding to a hazard ratio (HR) of 33.8 (95%CI 18-64, p<10-6).
Among FHR24 evaluable pts, 37 (13.4%) were FHR24, and 29 (10.5%) died without MM progression; excluding non-PD deaths, FHR24 rate was 15%. Among ASCT-treated, FHR24 was 8% and among non-ASCT-treated, the FHR24 was 16%. FHR24 occurred in 14.6% of pts on quads vs 21% on triplets, while, among ASCT-treated, FHR occurred in 8% of pts on quads vs 13% on triplets; among the non-ASCT treated in 25% and 23% respectively. The 2-year OS post PD was 55% for FHR24 vs 96% for the rest of the pts (HR : 10.5; 95%CI 4.6-23.6, p<10-6).
Among FHR36 evaluable pts, 26 (16%) were FHR36, and 34 (21%) died without progression; excluding non-PD deaths, FHR36 rate was 18.6%. Among ASCT-treated, FHR36 was 15% and among pts that did not receive ASCT the FHR36 was 43%. FHR36 occurred in 23.5% of pts on quads vs 36% on triplets (p=0.054), while, among ASCT-treated, FHR occurred in 12.7% of pts on quads vs 20.7% on triplets and among the non-ASCT treated in 42.6% and 43% respectively. The 2-year OS post PD was 60% for FHR36 vs 94% for the rest of the pts (HR: 8; 95%CI 3.5-19, p<10-6).
Baseline characteristics associated with FHR18 and FHR24 were disease stage [ISS (p=0.001), R-ISS (p=0.003), R2-ISS (p<0.001)], IMS CGS high risk (HR) cytogenetics (p<0.001), hypercalcemia (p=0.039), anemia (Hgb<10 gr/dl) (p=0.010), low PLT counts (p=0.002) while ASCT (p<0.001) and ≥VGPR in the first 6 months of therapy (p<0.001) were associated with lower risk. The use of quads vs triplets did not impact FHR18 (p=0.208). Among the smaller group of FHR36 evaluable pts, disease stage [ISS (p=0.002), R-ISS (p=0.002), R2-ISS (p=0.006)], but not IMS CGS HR cytogenetics were associated with early PD; ASCT (p<0.001), ≥VGPR in the first 6 months, and marginally of quads vs triplets (p=0.054), were associated with lower risk.
Cconclusion: in pts receiving antiCD38-based induction, followed by antiCD38-based maintenance, relapsing within 36 months after start of therapy, identifies a clinical entity with very poor outcomes. Current definitions of functional high-risk MM warrant refinement to include those relapsing within 36 months. ASCT/consolidation and deeper early responses mitigate the risk of early PD but quad induction showed modest effect. While high-risk cytogenetics increase the risk of early PD there is still a need for tools that improve early identification of those at risk of early PD and for early implementation of novel immune therapies.
DISCLOSURES
Meletios-Athanasios (Thanos) C. Dimopoulos, MD: Bristol Myers Squibb - Honoraria; Sanofi - Honoraria; Janssen - Honoraria; BeiGene - Honoraria; Amgen - Honoraria; Regeneron - Honoraria; Swixx BioPharma - Honoraria; GSK - Honoraria; Takeda - Honoraria; Menarini - Honoraria; AstraZeneca - Honoraria; Takeda - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Swixx BioPharma - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)